DUBLIN, May 20, 2024 /PRNewswire/ -- Fast Company announced that the Medtronic MiniMed™ 780G automated insulin delivery system has been recognized in the Best World-Changing Idea, North America ...

Medtronic plc’s MDT most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of ...

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures New data sought to evaluate the MiniMed™ 780G ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has approved an expanded indication for the ...

Medtronic has reported three milestones in the US, expanding access to its MiniMed 780G insulin delivery system for individuals with type 1 diabetes (T1D) and insulin-requiring type 2 diabetes (T2D).

With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn ...

Data from the LENNY trial, recently published in The Lancet Diabetes & Endocrinology, demonstrated the safety and efficacy i of the MiniMed™ 780G system in children aged 2-6 years old with type 1 ...

Medtronic has commercially launched its MiniMed 780G system in the US, now integrated with Abbott’s Instinct sensor. The Instinct sensor utilises Abbott’s continuous glucose monitoring (CGM) ...

A first-of-its-kind meta-analysis comparing multiple automated insulin delivery (AID) systems in people with type 1 diabetes has found that Medtronic's MiniMed 780G achieved the highest time in target ...

The FDA has approved Medtronic’s MiniMed 780G automated insulin delivery (AID) system for use in type 2 diabetes (T2D). At the same time, FDA also cleared the MiniMed SmartGuard algorithm as an ...